Stifel Nicolaus Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective trimmed by Stifel Nicolaus from $10.00 to $5.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a hold rating on the stock.

Other research analysts have also issued reports about the stock. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research note on Wednesday, January 8th. Canaccord Genuity Group cut their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company decreased their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Piper Sandler cut their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reduced their target price on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a report on Wednesday, January 15th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus target price of $9.45.

Health Catalyst Stock Performance

Shares of HCAT opened at $4.30 on Thursday. The stock has a market capitalization of $261.46 million, a P/E ratio of -3.18 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24. The company’s fifty day moving average is $6.03 and its two-hundred day moving average is $7.24.

Insider Buying and Selling

In related news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the transaction, the insider now directly owns 236,950 shares in the company, valued at $2,118,333. The trade was a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jason Alger sold 19,599 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $163,063.68. Following the completion of the sale, the chief financial officer now directly owns 86,712 shares in the company, valued at approximately $721,443.84. The trade was a 18.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 87,610 shares of company stock worth $664,043 in the last three months. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in shares of Health Catalyst during the fourth quarter valued at $29,000. Group One Trading LLC lifted its holdings in Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after purchasing an additional 2,260 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter worth about $34,000. Aquatic Capital Management LLC acquired a new stake in shares of Health Catalyst during the 4th quarter worth about $63,000. Finally, Stoneridge Investment Partners LLC purchased a new stake in shares of Health Catalyst during the fourth quarter worth about $77,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.